Post-transplant Lymphoproliferative Disorder Clinical Trial
Official title:
Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Patients with post transplant lymphoproliferative disorder (PTLD) that have been treated
with at least one type of chemotherapy, but whose lymphoma is not responding or coming back
after the previous treatment will be asked to participate in this study.
This clinical trial uses a drug called Obinutuzumab. The Food and Drug Administration (FDA)
has approved Obinutuzumab for sale in the United States for certain diseases. Obinutuzumab
is still being studied in clinical trials to learn more about what its side effects are and
whether or not it is effective in the disease or condition being studied. Obinutuzumab is
considered an investigational drug in this study
Obinutuzumab (GA101) is an antibody directed against cluster of differentiation antigen 20
(CD20). Antibodies are protein that are part of the immune system that can target cancer
cells. Obinutuzumab sticks to a target called CD20. CD20 is an important molecule on some
cancer cells (including non-Hodgkin lymphoma) and some normal cells of the immune system.
This study is being done to test if the study drug has an effect on post transplant
lymphoproliferative disorder and to see how lymphoma will respond to the study drug.
Primary Objective:
• To determine the overall response rate of obinutuzumab in relapsed/refractory
post-transplant lymphoproliferative disorder (PTLD) in both solid organ transplant (SOT) and
bone marrow transplant (BMT) patients
Secondary Objectives:
- Complete remission (CR) rate
- Duration of response (DOR)
- Progression free survival (PFS)
- Overall survival (OS)
- Time to treatment failure (TTF)
- Safety and tolerability of obinutuzumab
Patient Population:
Relapsed or refractory post-transplant lymphoproliferative disorder (PTLD) patients who have
received at least one prior therapy
Study Design:
Phase II study of single agent obinutuzumab in relapsed/refractory (RR) post-transplant
lymphoproliferative disorder (PTLD) in both SOT and BMT patients
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02153580 -
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Terminated |
NCT04337827 -
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
|
Phase 2 | |
| Active, not recruiting |
NCT01815749 -
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT06040320 -
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
|
Phase 1/Phase 2 | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT01254578 -
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
|
Phase 1 | |
| Terminated |
NCT02763254 -
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
|
Phase 2 | |
| Recruiting |
NCT02580539 -
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT01748721 -
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
| Terminated |
NCT01434472 -
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03546101 -
Early Detection of Epstein-Barr Virus Related Disease.
|
||
| Completed |
NCT01129193 -
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
|
Phase 1 | |
| Completed |
NCT01129180 -
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
|
Phase 1 | |
| Terminated |
NCT01116154 -
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
|
Phase 1 | |
| Terminated |
NCT00354185 -
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT00006251 -
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01805037 -
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
|
Phase 1/Phase 2 |